Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349064 | 0.84 | BDKRB1 (0.63) | BDKRB1NPC1RAB9AMAPTLMNA | |
| SCHEMBL927386 | 0.83 | NPC1 (0.57) | NPC1RAB9AMAPTLMNAPKM | |
| Acetic Acid SCHEMBL29111011 | 0.82 | LMNA (0.54) | NPC1RAB9AMAPTLMNAPKM | |
| SCHEMBL13834543 | 0.74 | NPC1 (0.49) | NPC1RAB9AMAPTLMNAPKM | |
| SCHEMBL6357667 | 0.74 | BDKRB1 (1.00) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL13834986 | 0.73 | NPC1 (0.48) | NPC1RAB9AMAPTLMNAPKM | |
| SCHEMBL5350707 | 0.73 | KDM4E (0.54) | NPC1RAB9AMAPTLMNAPKM | |
| SCHEMBL4145574 | 0.73 | PKM (0.54) | NPC1RAB9AMAPTLMNAPKM | |
| SCHEMBL5758848 | 0.72 | F10 (0.53) | NPC1RAB9AMAPTLMNAPKM | |
| SCHEMBL30662716 | 0.72 | PKM (0.53) | NPC1RAB9AMAPTLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | MERCK & CO., INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261327-A1 | 2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885NPC1 2454/4885RAB9A 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.